LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Jang, Joonseong"
  2. AU="Sergio Lafuente-Arroyo"
  3. AU="Löppönen, Heikki"
  4. AU="Santos, Maria Leonor"
  5. AU=Saluja Bharat
  6. AU="Nezhadi, Akram"
  7. AU=Dhar Debojyoti
  8. AU="Chandrappa S"
  9. AU="Cole, Kevin"
  10. AU=De Ceukelaire Wim
  11. AU=Tomatis L
  12. AU=Chandra Sharad
  13. AU="Mishra, Malvika"
  14. AU="Bruggemann, Kira"
  15. AU="Miura, Tanya A."
  16. AU="Kobeasy, Mohamed I."
  17. AU="Sonthonnax, Florian" AU="Sonthonnax, Florian"
  18. AU="Wang, Rongzu"

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel ; Online: Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice.

    Shin, Yujin / Lee, Mijeong / Lee, Dongju / Jang, Joonseong / Shin, Soon Shik / Yoon, Michung

    International journal of molecular sciences

    2021  Band 22, Heft 7

    Abstract: Fibrates, including fenofibrate, are a class of hypolipidemic drugs that activate peroxisome proliferator-activated receptor α (PPARα), which in-turn regulates the expression of lipid and lipoprotein metabolism genes. We investigated whether fenofibrate ... ...

    Abstract Fibrates, including fenofibrate, are a class of hypolipidemic drugs that activate peroxisome proliferator-activated receptor α (PPARα), which in-turn regulates the expression of lipid and lipoprotein metabolism genes. We investigated whether fenofibrate can reduce visceral obesity and nonalcoholic fatty liver disease via adipose tissue PPARα activation in female ovariectomized (OVX) C57BL/6J mice fed a high-fat diet (HFD), a mouse model of obese postmenopausal women. Fenofibrate reduced body weight gain (-38%,
    Mesh-Begriff(e) Adipocytes/drug effects ; Animals ; Diet, High-Fat ; Drug Evaluation, Preclinical ; Dyslipidemias/prevention & control ; Fatty Liver/prevention & control ; Female ; Fenofibrate/pharmacology ; Fenofibrate/therapeutic use ; Hypolipidemic Agents/pharmacology ; Hypolipidemic Agents/therapeutic use ; Intra-Abdominal Fat/metabolism ; Mice, Inbred C57BL ; Obesity, Abdominal/prevention & control ; Ovariectomy ; PPAR gamma/metabolism ; Mice
    Chemische Substanzen Hypolipidemic Agents ; PPAR gamma ; Fenofibrate (U202363UOS)
    Sprache Englisch
    Erscheinungsdatum 2021-04-01
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms22073675
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: The herbal extract ALS-L1023 from Melissa officinalis alleviates visceral obesity and insulin resistance in obese female C57BL/6J mice.

    Lee, Dongju / Shin, Yujin / Jang, Joonseong / Park, Yonghyun / Ahn, Jiwon / Jeong, Sunhyo / Shin, Soon Shik / Yoon, Michung

    Journal of ethnopharmacology

    2020  Band 253, Seite(n) 112646

    Abstract: Ethnopharmacological relevance: Melissa officinalis L. (Labiatae; lemon balm) has traditionally been used as a medicinal herb to treat stress, anxiety, and insomnia. Current reports suggest that not only chronic stress stimulates angiogenesis, but ... ...

    Abstract Ethnopharmacological relevance: Melissa officinalis L. (Labiatae; lemon balm) has traditionally been used as a medicinal herb to treat stress, anxiety, and insomnia. Current reports suggest that not only chronic stress stimulates angiogenesis, but angiogenesis also regulates adipogenesis and obesity. Because the herbal extract ALS-L1023 from Melissa officinalis inhibits angiogenesis, we hypothesized that ALS-L1023 could suppress visceral obesity and insulin resistance in obese female C57BL/6J mice, a mouse model of obese premenopausal women.
    Materials and methods: The mice were grouped and fed for 16 weeks as follows: 1) low-fat diet (LFD), 2) high-fat diet (HFD), or 3) HFD supplemented with 0.4 or 0.8% ALS-L1023. Variables and determinants of visceral obesity, insulin resistance, and pancreatic dysfunction were then assessed via blood analysis, histology, immunohistochemistry, and real-time polymerase chain reaction.
    Results: ALS-L1023 decreased weight gain, visceral adipocyte size, and serum lipid levels in HFD-fed obese mice. ALS-L1023 also normalized hyperglycemia and hyperinsulinemia and concomitantly reduced blood glucose levels during oral glucose tolerance tests. The pancreatic islet size and insulin-positive β-cell area were significantly reduced in ALS-L1023-treated mice compared with untreated obese controls, reaching a level similar to that of LFD-fed lean mice. ALS-L1023 suppressed pancreatic lipid accumulation, infiltration of inflammatory cells, and collagen levels. ALS-L1023 treatment altered the pancreatic expression of genes involved in steatosis, inflammation, and fibrosis.
    Conclusions: Our findings indicate that the herbal extract ALS-L1023 from Melissa officinalis not only inhibits visceral obesity, but also attenuates the increased fasting blood glucose, impaired glucose tolerance, and pancreatic dysfunction seen in female obese mice. These results suggest that ALS-L1023 may be effective in the prevention of visceral obesity and insulin resistance in obese premenopausal women.
    Mesh-Begriff(e) Adipocytes/drug effects ; Adipocytes/pathology ; Animals ; Anti-Obesity Agents/therapeutic use ; Blood Glucose/analysis ; Fatty Acids, Nonesterified/blood ; Female ; Fibrosis ; Insulin Resistance ; Melissa ; Mice, Inbred C57BL ; Obesity, Abdominal/blood ; Obesity, Abdominal/drug therapy ; Obesity, Abdominal/pathology ; Pancreas/drug effects ; Pancreas/pathology ; Plant Extracts/therapeutic use ; Triglycerides/blood
    Chemische Substanzen ALS-L1023 ; Anti-Obesity Agents ; Blood Glucose ; Fatty Acids, Nonesterified ; Plant Extracts ; Triglycerides
    Sprache Englisch
    Erscheinungsdatum 2020-02-03
    Erscheinungsland Ireland
    Dokumenttyp Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2020.112646
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1494: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: The polyherbal composition Gyeongshingangjeehwan 18 attenuates glucose intolerance and pancreatic steatosis in C57BL/6J mice on a high-fat diet

    Jang, Joonseong / Park, Yonghyun / Lee, Dongju / Lee, Haerim / Lim, Jonghoon / Yoon, Seol Ah / Lee, Hyunghee / Ahn, Jiwon / Jeong, Sunhyo / Shin, Soon Shik / Yoon, Michung

    Journal of ethnopharmacology. 2019 Aug. 10, v. 240

    2019  

    Abstract: Ethnopharmacologic relevance: Gyeongshingangjeehwan 18 (GGEx18) is a polyherbal composition derived from Ephedra sinica Stapf (Ephedraceae), Laminaria japonica Aresch (Laminariaceae), and Rheum palmatum L. (Polygonaceae) that is used as an antiobesity ... ...

    Abstract Ethnopharmacologic relevance: Gyeongshingangjeehwan 18 (GGEx18) is a polyherbal composition derived from Ephedra sinica Stapf (Ephedraceae), Laminaria japonica Aresch (Laminariaceae), and Rheum palmatum L. (Polygonaceae) that is used as an antiobesity drug in Korean clinics. Its constituents are traditionally known to combat obesity, dyslipidemia, and insulin resistance.This study was undertaken to investigate the effects of GGEx18 on glucose metabolism and pancreatic steatosis in obese C57BL/6 J mice fed a high-fat diet (HFD) and to examine the related cellular and molecular mechanisms.The mice were grouped and fed for 13 weeks as follows: 1) low-fat diet, 2) HFD, or 3) HFD supplemented with GGEx18 (500 mg/kg/day). Various factors affecting insulin sensitivity and pancreatic function were then assessed via blood analysis, histology, immunohistochemistry, and real-time polymerase chain reaction.GGEx18 treatment of obese mice reduced body weight, total fat, and visceral fat mass. GGEx18 inhibited hyperglycemia and hyperinsulinemia and improved glucose and insulin tolerance. GGEx18 also decreased serum leptin levels and concomitantly increased adiponectin levels. Furthermore, GGEx18-treated mice exhibited reduced pancreatic fat accumulation and normalized insulin-secreting β-cell area. GGEx18 increased pancreatic expression of genes promoting fatty acid β-oxidation (i.e., MCAD and VLCAD), whereas expression levels of lipogenesis-related genes (i.e., PPARγ, SREBP-1c, and FAS) declined.GGEx18 curtailed impaired glucose metabolism and pancreatic steatosis in our mouse model by regulating pancreatic genes that govern lipid metabolism and improving insulin sensitivity. This composition may benefit patients with impaired glucose tolerance, insulin resistance, and pancreatic dysfunction.
    Schlagwörter Ephedra sinica ; Rheum palmatum ; Saccharina japonica ; adiponectin ; animal disease models ; anti-obesity agents ; beta oxidation ; blood serum ; fatty acids ; gene expression ; genes ; glucose ; glucose tolerance ; hematologic tests ; high fat diet ; hyperglycemia ; hyperinsulinemia ; hyperlipidemia ; immunohistochemistry ; insulin ; insulin resistance ; islets of Langerhans ; leptin ; low fat diet ; mice ; obesity ; patients ; peroxisome proliferator-activated receptor gamma ; traditional medicine ; visceral fat
    Sprache Englisch
    Erscheinungsverlauf 2019-0810
    Erscheinungsort Elsevier B.V.
    Dokumenttyp Artikel
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2019.111943
    Datenquelle NAL Katalog (AGRICOLA)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Bonn

    Z 90/710: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel ; Online: The polyherbal composition Gyeongshingangjeehwan 18 attenuates glucose intolerance and pancreatic steatosis in C57BL/6J mice on a high-fat diet.

    Jang, Joonseong / Park, Yonghyun / Lee, Dongju / Lee, Haerim / Lim, Jonghoon / Yoon, Seol Ah / Lee, Hyunghee / Ahn, Jiwon / Jeong, Sunhyo / Shin, Soon Shik / Yoon, Michung

    Journal of ethnopharmacology

    2019  Band 240, Seite(n) 111943

    Abstract: Ethnopharmacologic relevance: Gyeongshingangjeehwan 18 (GGEx18) is a polyherbal composition derived from Ephedra sinica Stapf (Ephedraceae), Laminaria japonica Aresch (Laminariaceae), and Rheum palmatum L. (Polygonaceae) that is used as an antiobesity ... ...

    Abstract Ethnopharmacologic relevance: Gyeongshingangjeehwan 18 (GGEx18) is a polyherbal composition derived from Ephedra sinica Stapf (Ephedraceae), Laminaria japonica Aresch (Laminariaceae), and Rheum palmatum L. (Polygonaceae) that is used as an antiobesity drug in Korean clinics. Its constituents are traditionally known to combat obesity, dyslipidemia, and insulin resistance.
    Objective: This study was undertaken to investigate the effects of GGEx18 on glucose metabolism and pancreatic steatosis in obese C57BL/6 J mice fed a high-fat diet (HFD) and to examine the related cellular and molecular mechanisms.
    Materials and methods: The mice were grouped and fed for 13 weeks as follows: 1) low-fat diet, 2) HFD, or 3) HFD supplemented with GGEx18 (500 mg/kg/day). Various factors affecting insulin sensitivity and pancreatic function were then assessed via blood analysis, histology, immunohistochemistry, and real-time polymerase chain reaction.
    Results: GGEx18 treatment of obese mice reduced body weight, total fat, and visceral fat mass. GGEx18 inhibited hyperglycemia and hyperinsulinemia and improved glucose and insulin tolerance. GGEx18 also decreased serum leptin levels and concomitantly increased adiponectin levels. Furthermore, GGEx18-treated mice exhibited reduced pancreatic fat accumulation and normalized insulin-secreting β-cell area. GGEx18 increased pancreatic expression of genes promoting fatty acid β-oxidation (i.e., MCAD and VLCAD), whereas expression levels of lipogenesis-related genes (i.e., PPARγ, SREBP-1c, and FAS) declined.
    Discussion and conclusion: GGEx18 curtailed impaired glucose metabolism and pancreatic steatosis in our mouse model by regulating pancreatic genes that govern lipid metabolism and improving insulin sensitivity. This composition may benefit patients with impaired glucose tolerance, insulin resistance, and pancreatic dysfunction.
    Mesh-Begriff(e) Animals ; Anti-Obesity Agents/pharmacology ; Anti-Obesity Agents/therapeutic use ; Diet, High-Fat ; Gene Expression/drug effects ; Glucose Intolerance/drug therapy ; Glucose Intolerance/metabolism ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Insulin Resistance ; Lipid Metabolism/drug effects ; Male ; Mice, Inbred C57BL ; Obesity/drug therapy ; Obesity/metabolism ; Pancreas/drug effects ; Pancreas/metabolism ; Pancreatic Diseases/drug therapy ; Pancreatic Diseases/metabolism ; Plant Extracts/pharmacology ; Plant Extracts/therapeutic use ; Plant Preparations/pharmacology ; Plant Preparations/therapeutic use
    Chemische Substanzen Anti-Obesity Agents ; Hypoglycemic Agents ; Plant Extracts ; Plant Preparations ; gyeongshingangjeehwan
    Sprache Englisch
    Erscheinungsdatum 2019-05-07
    Erscheinungsland Ireland
    Dokumenttyp Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2019.111943
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1494: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: The polyherbal drug GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits hepatic steatosis and fibroinflammtion in high-fat diet-induced obese mice.

    Lim, Jonghoon / Lee, Haerim / Ahn, Jiwon / Kim, Jeongjun / Jang, Joonseong / Park, Yonghyun / Jeong, Birang / Yang, Heejung / Shin, Soon Shik / Yoon, Michung

    Journal of ethnopharmacology

    2018  Band 225, Seite(n) 31–41

    Abstract: Ethnopharmacological relevance: The herbal composition Gyeongshingangjeehwan 18 (GGEx18), composed of Rheum palmatum L. (Polygonaceae), Laminaria japonica Aresch (Laminariaceae), and Ephedra sinica Stapf (Ephedraceae), is used as an antiobesity drug in ... ...

    Abstract Ethnopharmacological relevance: The herbal composition Gyeongshingangjeehwan 18 (GGEx18), composed of Rheum palmatum L. (Polygonaceae), Laminaria japonica Aresch (Laminariaceae), and Ephedra sinica Stapf (Ephedraceae), is used as an antiobesity drug in Korean clinics. The constituents of GGEx18 have traditionally been reported to inhibit obesity and related metabolic diseases such as insulin resistance and dyslipidemia.
    Objective: This study investigated the effects of GGEx18 on nonalcoholic fatty liver disease (NAFLD) in mice fed a high-fat diet (HFD) and the underlying cellular and molecular mechanisms involved.
    Methods: C57BL/6 J mice were fed either a low-fat diet (LFD), an HFD, or an HFD supplemented with GGEx18 (125, 250, or 500 mg/kg of body weight/day). After 13 weeks, blood analyses, histology, immunohistochemistry, and real-time PCR were performed to assess NAFLD development in these mice.
    Results: Mice fed an HFD had increases in body weight, epididymal adipose tissue mass, adipocyte size, and adipose expression of inflammation-related genes compared with those fed an LFD. These increases were ameliorated in mice treated with 500 mg/kg/day GGEx18 without affecting food consumption profiles. GGEx18 not only decreased serum levels of triglycerides, free fatty acids, and alanine aminotransferase, but also decreased hepatic lipid accumulation, numbers of mast cells and α-smooth muscle actin-positive cells, and collagen levels induced by an HFD. Consistent with the histological data, the hepatic expression of lipogenesis-, inflammation-, and fibrosis-related genes was lower, while hepatic fatty acid β-oxidation-related gene expression was higher, in mice receiving GGEx18 compared to mice fed only the HFD.
    Discussion and conclusion: These results indicate that GGEx18 attenuates visceral obesity and NAFLD, in part by altering the expression of genes involved in hepatic steatosis and fibroinflammation in HFD-induced obese mice. These findings suggest that GGEx18 may be effective for preventing and treating NAFLD associated with visceral obesity.
    Mesh-Begriff(e) Animals ; Anti-Inflammatory Agents/therapeutic use ; Anti-Obesity Agents/therapeutic use ; Diet, High-Fat ; Ephedra sinica ; Gene Expression Regulation/drug effects ; Laminaria ; Lipid Metabolism/drug effects ; Liver/drug effects ; Liver/metabolism ; Liver/pathology ; Male ; Mice, Inbred C57BL ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/genetics ; Non-alcoholic Fatty Liver Disease/pathology ; Obesity, Abdominal/drug therapy ; Obesity, Abdominal/genetics ; Obesity, Abdominal/pathology ; Phytotherapy ; Plant Extracts ; Plant Preparations/therapeutic use ; Rheum
    Chemische Substanzen Anti-Inflammatory Agents ; Anti-Obesity Agents ; Plant Extracts ; Plant Preparations ; gyeongshingangjeehwan
    Sprache Englisch
    Erscheinungsdatum 2018-06-26
    Erscheinungsland Ireland
    Dokumenttyp Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2018.06.034
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1494: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang